Neutropenia febril grave inducida por mesalazina

Freire González, Mercedes; Moro-Agud, Marta; Oviedo Briones, Myriam.
Med. clín (Ed. impr.) ; 151(6): e33-e34, sept. 2018. graf
Artículo en Español | IBECS (España) | ID: ibc-173931

Documentos relacionados

  1. Plasma Microbial Cell-free DNA Next-generation Sequencing in the Diagnosis and Management of Febrile Neutropenia.
  2. The application of nanopore targeted sequencing in the diagnosis and antimicrobial treatment guidance of bloodstream infection of febrile neutropenia patients with hematologic disease.
  3. Pediatric Invasive Fungal Risk Score in Cancer and Hematopoietic Stem Cell Transplantation Patients With Febrile Neutropenia.
  4. Febrile neutropenia management and outcomes in hematopoietic cell transplantation for chronic granulomatous disease.
  5. Use of wide-spectrum antimicrobials with blood culture tests during chemotherapy as an accurate marker of febrile neutropenia in the DPC database: A validation study.
  6. Managing febrile neutropenia in the UK in 2020.
  7. Procalcitonin Clearance, CD64, and HLA-DR as Predictors of Outcome in Febrile Neutropenic Children With Lymphoreticular Malignancies.
  8. Early Antibiotic Discontinuation or De-escalation in High-Risk Patients With AML With Febrile Neutropenia and Prolonged Neutropenia.
  9. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.
  10. Absolute Monocyte Count as Early and Safe Marker for Antibiotic Cessation in Febrile Neutropenia Without Etiology in Pediatric Oncology Patients.